ATE528396T1 - Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften - Google Patents
Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaftenInfo
- Publication number
- ATE528396T1 ATE528396T1 AT05809866T AT05809866T ATE528396T1 AT E528396 T1 ATE528396 T1 AT E528396T1 AT 05809866 T AT05809866 T AT 05809866T AT 05809866 T AT05809866 T AT 05809866T AT E528396 T1 ATE528396 T1 AT E528396T1
- Authority
- AT
- Austria
- Prior art keywords
- polypeptide
- amino acids
- mutagenesis
- libraries
- look
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58591804P | 2004-07-06 | 2004-07-06 | |
PCT/US2005/024140 WO2006023144A2 (en) | 2004-07-06 | 2005-07-06 | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE528396T1 true ATE528396T1 (de) | 2011-10-15 |
Family
ID=35968026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05809866T ATE528396T1 (de) | 2004-07-06 | 2005-07-06 | Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften |
Country Status (9)
Country | Link |
---|---|
US (1) | US9012369B2 (de) |
EP (1) | EP1774019B1 (de) |
JP (2) | JP4939410B2 (de) |
AT (1) | ATE528396T1 (de) |
BR (1) | BRPI0513155B1 (de) |
CA (1) | CA2572917C (de) |
ES (1) | ES2372503T3 (de) |
MX (1) | MX2007000105A (de) |
WO (1) | WO2006023144A2 (de) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP2006381B1 (de) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern |
EP2012829A4 (de) * | 2006-04-24 | 2010-04-21 | Protelix Inc | Verfahren zur herstellung eines viralen impfstoffes und therapeutischer peptid-antigene |
CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
EP2118281A2 (de) | 2007-02-12 | 2009-11-18 | Codexis, Inc. | Struktur-wirkungs-beziehungen |
EP2392653B1 (de) * | 2007-07-12 | 2014-03-19 | New England Biolabs, Inc. | Restriktionsendonukleasen mit hoher Fidelität |
JP5566108B2 (ja) * | 2007-09-26 | 2014-08-06 | 中外製薬株式会社 | 抗il−6レセプター抗体 |
EP4339294A3 (de) | 2007-09-26 | 2024-10-16 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in cdr |
MY163473A (en) | 2007-09-26 | 2017-09-15 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
US20110189203A1 (en) | 2007-11-27 | 2011-08-04 | Ablynx N.V. | Immunoglobulin constructs |
US20110118447A1 (en) * | 2007-12-31 | 2011-05-19 | Xoma Technology Ltd. | Methods and materials for targeted affinity enhancement |
KR20240113501A (ko) | 2008-04-11 | 2024-07-22 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
CA2723277A1 (en) | 2008-05-02 | 2009-11-05 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2010111707A1 (en) | 2009-03-27 | 2010-09-30 | Sapphire Energy, Inc. | Variant isoprenoid producing enzymes and uses thereof |
US10618964B2 (en) | 2009-04-10 | 2020-04-14 | Ablynx N.V. | Nanobody against IL-6R |
KR20130119990A (ko) | 2009-04-10 | 2013-11-01 | 아블린쓰 엔.브이. | Il-6r에 대한 개선된 아미노산 서열 및 il-6r 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드 |
CA2764398A1 (en) | 2009-06-05 | 2010-12-09 | Erik Depla | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
EP3248987A1 (de) | 2010-07-30 | 2017-11-29 | Novartis AG | Fibronectin-cradle-moleküle und bibliotheken |
EP2619226B1 (de) * | 2010-09-22 | 2018-09-12 | Amgen Inc. | Träger-immunglobuline und verwendungen davon |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
AU2012311443B2 (en) | 2011-09-23 | 2016-12-01 | Ablynx Nv | Prolonged inhibition of interleukin-6 mediated signaling |
ES2819075T3 (es) | 2011-10-11 | 2021-04-14 | Viela Bio Inc | Matrices de soporte derivadas de TN3 específicas para CD40L y sus métodos de empleo |
CN113416256A (zh) | 2011-11-30 | 2021-09-21 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
KR20140132748A (ko) | 2012-03-02 | 2014-11-18 | 아블린쓰 엔.브이. | 슈도모나스 애루기노사 pcrv 결합 단일 가변 도메인 항체 |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
US10309969B2 (en) * | 2013-01-24 | 2019-06-04 | Abtlas Co., Ltd. | Protein combination-based FV library, and preparation method therefor |
EP2989202B1 (de) | 2013-04-25 | 2019-04-10 | Sutro Biopharma, Inc. | Die verwendung des lambda-gam proteins in der ribosomen-display-technologie |
EP2989239B1 (de) * | 2013-04-25 | 2018-07-04 | Sutro Biopharma, Inc. | Auswahl von fab-fragmenten anhand von ribosomaler display-technik |
JP6442404B2 (ja) | 2013-06-11 | 2018-12-19 | 国立研究開発法人国立精神・神経医療研究センター | 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法 |
US9409139B2 (en) | 2013-08-05 | 2016-08-09 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
JP2017534617A (ja) | 2014-10-21 | 2017-11-24 | アブリンクス エン.ヴェー. | Il−6r関連疾患の処置 |
CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
SG11201705093UA (en) | 2015-02-27 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Composition for treating il-6-related diseases |
KR20240093725A (ko) | 2015-03-12 | 2024-06-24 | 메디뮨 엘엘씨 | 알부민 융합 단백질의 정제 방법 |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
PL3299810T3 (pl) | 2015-05-19 | 2021-12-13 | National Center Of Neurology And Psychiatry | Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm) |
ES2881683T3 (es) | 2015-05-21 | 2021-11-30 | Full Spectrum Genetics Inc | Procedimiento para mejorar las características de las proteínas |
CA2998169A1 (en) * | 2015-09-18 | 2017-03-23 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
CN108603307A (zh) | 2015-12-01 | 2018-09-28 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
USD782516S1 (en) | 2016-01-19 | 2017-03-28 | Apple Inc. | Display screen or portion thereof with graphical user interface |
EP3500672A4 (de) | 2016-08-22 | 2020-05-20 | Twist Bioscience Corporation | De-novo-synthetisierte nukleinsäure-bibliotheken |
JP6871364B2 (ja) | 2016-09-21 | 2021-05-12 | ツイスト バイオサイエンス コーポレーション | 核酸に基づくデータ保存 |
CA3047128A1 (en) | 2016-12-16 | 2018-06-21 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
CA3054303A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
WO2018170169A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
WO2018231872A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
WO2019051501A1 (en) | 2017-09-11 | 2019-03-14 | Twist Bioscience Corporation | PROTEINS BINDING TO GPCR AND METHODS OF SYNTHESIS |
EP3698808A4 (de) | 2017-10-20 | 2021-07-14 | Hyogo College Of Medicine | Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion |
KR102637566B1 (ko) | 2017-10-20 | 2024-02-16 | 트위스트 바이오사이언스 코포레이션 | 폴리뉴클레오타이드 합성을 위한 가열된 나노웰 |
US10936953B2 (en) | 2018-01-04 | 2021-03-02 | Twist Bioscience Corporation | DNA-based digital information storage with sidewall electrodes |
KR20210013128A (ko) | 2018-05-18 | 2021-02-03 | 트위스트 바이오사이언스 코포레이션 | 핵산 하이브리드화를 위한 폴리뉴클레오타이드, 시약 및 방법 |
AU2020229349A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
CA3131691A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
EP3987019A4 (de) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | Barcode-basierte nukleinsäuresequenzanordnung |
EP4034566A4 (de) | 2019-09-23 | 2024-01-24 | Twist Bioscience Corporation | Variante nukleinsäurebibliotheken für crth2 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2078518T3 (es) | 1990-04-05 | 1995-12-16 | Roberto Crea | Mutagenesis por desplazamiento completo. |
EP1230269A2 (de) | 1999-11-03 | 2002-08-14 | Maxygen, Inc. | Erzeugung von antikörperdiversität |
AU784983B2 (en) * | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
ES2328345T3 (es) * | 2002-04-17 | 2009-11-12 | Bioren, Inc. | Bibliotecas universales para inmunoglobulinas. |
ATE374255T1 (de) * | 2002-04-17 | 2007-10-15 | Bioren Inc | Doping bei der walk-through-mutagenese |
KR20060034650A (ko) * | 2003-06-27 | 2006-04-24 | 바이오렌 인코포레이티드 | 룩-스루 돌연변이 |
-
2005
- 2005-07-06 ES ES05809866T patent/ES2372503T3/es active Active
- 2005-07-06 JP JP2007520506A patent/JP4939410B2/ja active Active
- 2005-07-06 CA CA2572917A patent/CA2572917C/en active Active
- 2005-07-06 WO PCT/US2005/024140 patent/WO2006023144A2/en active Application Filing
- 2005-07-06 US US11/571,088 patent/US9012369B2/en active Active
- 2005-07-06 BR BRPI0513155-3A patent/BRPI0513155B1/pt active IP Right Grant
- 2005-07-06 EP EP05809866A patent/EP1774019B1/de active Active
- 2005-07-06 AT AT05809866T patent/ATE528396T1/de not_active IP Right Cessation
- 2005-07-06 MX MX2007000105A patent/MX2007000105A/es active IP Right Grant
-
2011
- 2011-09-15 JP JP2011201518A patent/JP2012041347A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1774019A2 (de) | 2007-04-18 |
ES2372503T3 (es) | 2012-01-20 |
CA2572917C (en) | 2012-04-03 |
BRPI0513155B1 (pt) | 2021-07-20 |
US9012369B2 (en) | 2015-04-21 |
CA2572917A1 (en) | 2006-03-02 |
BRPI0513155A (pt) | 2008-04-29 |
JP2012041347A (ja) | 2012-03-01 |
US20080214406A1 (en) | 2008-09-04 |
JP2008505642A (ja) | 2008-02-28 |
EP1774019B1 (de) | 2011-10-12 |
JP4939410B2 (ja) | 2012-05-23 |
WO2006023144A2 (en) | 2006-03-02 |
EP1774019A4 (de) | 2009-05-20 |
WO2006023144A3 (en) | 2006-08-17 |
MX2007000105A (es) | 2007-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE528396T1 (de) | Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften | |
WO2005003345A3 (en) | Look-through mutagenesis | |
ES2078518T3 (es) | Mutagenesis por desplazamiento completo. | |
Camporeale et al. | K8 and K12 are biotinylated in human histone H4 | |
Tu et al. | Sequence analysis and molecular docking of antithrombotic peptides from casein hydrolysate by trypsin digestion | |
Ma et al. | Differential proteomic analysis of platelets suggested possible signal cascades network in platelets treated with salvianolic acid B | |
Lai et al. | The emerging role of the peptidome in biomarker discovery and degradome profiling | |
Schroeter et al. | Bone protein “extractomics”: comparing the efficiency of bone protein extractions of Gallus gallus in tandem mass spectrometry, with an eye towards paleoproteomics | |
ATE344456T1 (de) | Durch affinität ausgewählte unterschriftspeptide zur identifizierung und quantifizierung von proteinen | |
DE60139326D1 (de) | Detektion von peptiden | |
BR0112119A (pt) | Polipeptìdeo isolado, molécula de ácido nucléico isolado, vetor, célula hospedeira recombinante, método de produzir a proteìna zcyto21, anticorpo ou fragmento de anticorpo, método de detectar a presença da expressão do gene zcyto21 em uma amostra biológica | |
WO2002042427A3 (en) | Mass tags for quantitative analysis | |
Slagboom et al. | Analytical strategies in venomics | |
DE60109490D1 (de) | Umgekehrtes labelierungsverfahren zur schnellen identifikation von marker/ziel-proteinen | |
CN105277712B (zh) | 一种鉴定赖氨酸ε‑氨基侧链单甲基化修饰的方法 | |
JP2019507341A5 (de) | ||
Fu et al. | rMCP-2, the major rat mucosal mast cell protease, an analysis of its extended cleavage specificity and its potential role in regulating intestinal permeability by the cleavage of cell adhesion and junction proteins | |
ES2079621T3 (es) | Procedimiento de identificacion o de titulacion de proteinas y aplicaciones. | |
Zoumaro-Djayoon et al. | Targeted analysis of tyrosine phosphorylation by immuno-affinity enrichment of tyrosine phosphorylated peptides prior to mass spectrometric analysis | |
DE69902924D1 (de) | Neue methoden zum auffinden von liganden- und ziel-biomolekülen | |
ATE288589T1 (de) | Verfahren zur analyse von proteinen | |
SE0302559D0 (sv) | Method | |
WO2008142664A3 (en) | Exposed thymidine kinase 1 peptides, ligands and methods employing the same | |
WO2005005990A3 (en) | Inverse labeling method for the rapid identification of marker target proteins | |
Jiang et al. | Investigating the loss of major yolk proteins during the processing of sea cucumber (Apostichopus japonicus) using an MRM-based targeted proteomics strategy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |